STATERA BIOPHARMA
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch STAB and buy or sell other stocks, ETFs, and their options commission-free!About STAB
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Its proprietary product toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532 have applications in mitigation of radiation injury and neutropenia an anemia.
CEOMichael Kevin Handley, MBA
CEOMichael Kevin Handley, MBA
Employees16
Employees16
HeadquartersFort Collins, Colorado
HeadquartersFort Collins, Colorado
Founded2003
Founded2003
Employees16
Employees16
STAB Key Statistics
Market cap7.14K
Market cap7.14K
Price-Earnings ratio—
Price-Earnings ratio—
Dividend yield—
Dividend yield—
Average volume16.92K
Average volume16.92K
High today$0.0001
High today$0.0001
Low today$0.0001
Low today$0.0001
Open price$0.0001
Open price$0.0001
Volume400.00
Volume400.00
52 Week high$0.0133
52 Week high$0.0133
52 Week low$0.00
52 Week low$0.00
Stock Snapshot
STATERA BIOPHARMA(STAB) stock is priced at $0.00, giving the company a market capitalization of 7.14K.
During the trading session on 2026-04-05, STATERA BIOPHARMA(STAB) shares reached a daily high of $0.00 and a low of $0.00. At a current price of $0.00, the stock is 0.0% higher than the low and still 0.0% under the high.
Trading volume for STATERA BIOPHARMA(STAB) stock has reached 400, versus its average volume of 16.92K.
The stock's 52-week range extends from a low of $0.00 to a high of $0.01.
The stock's 52-week range extends from a low of $0.00 to a high of $0.01.
People also own
Based on the portfolios of people who own STAB. This list is generated using Robinhood data, and it’s not a recommendation.